- Home
- ZTR vs XOMA Comparison
ZTR vs XOMA Comparison
Compare ZTR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- XOMA
- Stock Information
- Founded
- ZTR 1988
- XOMA 1981
- Country
- ZTR Australia
- XOMA United States
- Employees
- ZTR N/A
- XOMA N/A
- Industry
- ZTR Investment Managers
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- XOMA Health Care
- Exchange
- ZTR Nasdaq
- XOMA Nasdaq
- Market Cap
- ZTR 349.4M
- XOMA 330.2M
- IPO Year
- ZTR N/A
- XOMA N/A
- Fundamental
- Price
- ZTR $6.37
- XOMA $32.47
- Analyst Decision
- ZTR
- XOMA Strong Buy
- Analyst Count
- ZTR 0
- XOMA 2
- Target Price
- ZTR N/A
- XOMA $69.50
- AVG Volume (30 Days)
- ZTR 219.4K
- XOMA 57.0K
- Earning Date
- ZTR 01-01-0001
- XOMA 08-13-2025
- Dividend Yield
- ZTR 12.09%
- XOMA N/A
- EPS Growth
- ZTR N/A
- XOMA N/A
- EPS
- ZTR N/A
- XOMA N/A
- Revenue
- ZTR N/A
- XOMA $44,952,000.00
- Revenue This Year
- ZTR N/A
- XOMA $82.30
- Revenue Next Year
- ZTR N/A
- XOMA $12.59
- P/E Ratio
- ZTR N/A
- XOMA N/A
- Revenue Growth
- ZTR N/A
- XOMA 194.98
- 52 Week Low
- ZTR $4.50
- XOMA $18.35
- 52 Week High
- ZTR $6.60
- XOMA $35.23
- Technical
- Relative Strength Index (RSI)
- ZTR 64.07
- XOMA 61.79
- Support Level
- ZTR $6.27
- XOMA $32.60
- Resistance Level
- ZTR $6.35
- XOMA $34.60
- Average True Range (ATR)
- ZTR 0.04
- XOMA 1.82
- MACD
- ZTR 0.01
- XOMA 0.09
- Stochastic Oscillator
- ZTR 85.06
- XOMA 66.75
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.